Lipfendra (enlicitide): what it is, in plain words

Last checked: November 4, 2026. Educational only, not medical advice. PeptideX is not affiliated with Merck or any drug maker.

What it is

Lipfendra (enlicitide) is a prescription tablet from Merck. FDA approved it in July 2026. Its label says it is used along with diet and exercise to lower LDL ("bad") cholesterol in adults with high cholesterol, including an inherited type called heterozygous familial hypercholesterolemia (HeFH). It belongs to a drug class called PCSK9 inhibitors. Merck describes it as a macrocyclic peptide.

How it works

Your liver uses LDL receptors to pull LDL cholesterol out of the blood. A protein called PCSK9 breaks those receptors down. Lipfendra blocks PCSK9, so more receptors stay available to clear LDL.

How it differs from statins

  • Statins reduce how much cholesterol your liver makes.
  • Lipfendra works on PCSK9, a different step, to help the liver clear LDL already in the blood.
  • In the trials FDA reviewed, people were already taking the most statin they could tolerate, and Lipfendra was added on top.

How it differs from other PCSK9 drugs

  • Earlier PCSK9 inhibitors are injections. Before Lipfendra, FDA notes, PCSK9 inhibitors were injectable therapies.
  • Lipfendra is a tablet taken by mouth once a day. Your prescriber explains how to take it.

What the trials showed

Two placebo-controlled trials in 3,207 adults on statins. At week 24, LDL fell by an average 56% (adults with or at high risk for heart disease) and 59% (adults with HeFH) compared with placebo (FDA).

Side effects listed on the label

In the HeFH trial, the most common side effects that happened more often than with placebo were diarrhea (7% vs 2% with placebo) and dizziness (9% vs 4%), per section 6 of the FDA label. In the other trial, side effects were similar to placebo. See the full prescribing information for all safety details.

Questions to ask your clinician

  • Is my LDL at goal on my current treatment?
  • Would a tablet or an injection fit me better?
  • Does my insurance cover it?

Sources (read Nov 4, 2026):

1. FDA press release, July 17, 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

2. FDA Drugs news: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-therapy-inhibits-proprotein-convertase-subtilisinkexin-type-9-pcsk9-lower

3. DailyMed label (updated July 15, 2026, NDA220848): https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=100ec543-fbd0-44fc-b740-db9cdff39145

4. Merck release, July 16, 2026: https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/